Oncology

Blog Navigating ER+ HER2- Early Breast Cancer Webinar Series Looking Ahead in ER+/HER2- Breast Cancer: Unpacking Long-Term Prognostic Factors Presenter: Dr. Jessica Leitsmann, Breast-Oncologist at the Breast Center of Elblandklinikum Radebeul Abstract: This webinar explored key insights from an international discussion on optimizing treatment for early ER-positive, HER2-negative breast cancer. Our expert emphasized the importance

Blog Navigating ER+ HER2- Early Breast Cancer Webinar Series Tailoring Treatment for Premenopausal Patients – Is there Still a Role for Gene-Expression Testing? Presenters: Michalis Kontos, Professor of Breast and General Surgery, National and Kapodistrian University of Athens and PD Dr. med Evelyn Klein, Klinik und Polyklinik für Frauenheilkunde der Technischen Universität München. Abstract: Breast

Blog Navigating ER+ HER2- Early Breast Cancer Webinar Series  What’s New for High-Risk Early Breast Cancer Patients in 2024 Presenter: Prof. Michael Untch, Head of the Interdisciplinary Breast Cancer Center at Helios Clinic Berlin-Buch, Germany and Prof. Frédérique Penault-Llorca, Centre Jean Perrin, Clermont Ferrand, France. Abstract:  The introduction of adjuvant CDK4/6 inhibition represents a major

L’un des plus grands défis dans le traitement du cancer est que chaque cancer se comporte différemment. Nombreuses questions se posent telles que : Va-t-il croître rapidement ou lentement? Va-t-il se propager à d’autres organes ou non? Pourrait-il revenir après le traitement ? Il existe dorénavant des outils innovants qui permettent d’y voir plus clair :

We are excited to announce that the EndoPredict test, a leading prognostic tool for early-stage breast cancer, is now available in Australia with NATA accreditation. This marks a significant step forward in providing Australian patients with cutting-edge genomic technology for personalized breast cancer care. EndoPredict is specifically designed for patients with early-stage ER+/HER2- breast cancer,

Eine der größten Herausforderungen bei der Behandlung von Krebs ist, dass sich jeder Krebs anders verhalten kann. Wird er schnell oder langsam wachsen? Wird er sich auf andere Organe ausbreiten oder nicht? Könnte er nach der Therapie wiederkommen? Kurze Fakten über genomische Tests Genom-Tests untersuchen das Innere von Krebszellen und ihre Gene, um einige dieser

One of the biggest challenges in treating cancer is that each one can behave differently to the next. Will it grow fast, or slow? Will it spread to other organs or not? Might it come back after therapy? Quick facts about genomic tests Genomic testing looks inside cancer cells at their genes to answer some

Prospective evidence demonstrates prognostic and predictive performance in clinical practice We are excited to share the latest prospective findings from a study entitled “Long-term prospective outcome data using EndoPredict as risk stratification and chemotherapy decision biomarker in hormone receptor-positive, HER2-negative early breast cancer”.1 This study, led by Evelyn Klein and her team, sheds light on

Supporting tailored therapy for more patients to optimize outcomes The National Institute for Health and Care Excellence (NICE) in the UK has issued a new guidance, endorsing the use of EndoPredict, a cutting-edge diagnostic tool to support healthcare providers to make decisions on the use of chemotherapy in patients with lymph node positive early ER+

Prognostic value of EndoPredict test in patients with hormone receptor positive, human epidermal growth factor receptor 2-negative primary breast cancer screened for the randomized, double-blind, phase III UNIRAD trial We are excited to share findings from a recently published analysis exploring the prognostic value of EndoPredict using prospectively collected data from node-positive ER+ HER2- breast